LabCorp to Announce Third Quarter Financial Results on October 24, 2018

BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 25, 2018--
LabCorp® (NYSE: LH) will release its third quarter 2018 financial
results before the market opens on Wednesday, October 24, 2018, and then
will host a conference call and webcast beginning at 9:00 a.m. EDT to
discuss the results. The earnings release and accompanying financial
information will be posted on the LabCorp
Investor Relations website.

Interested parties can access the conference call in listen-only mode by
dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253
internationally, using the passcode 7398818. In addition, a real-time
webcast of the conference call will be available on the LabCorp
Investor Relations website.

An audio replay of the conference call will be available from 1:00 p.m.
EDT on October 24, 2018, until 11:30 a.m. EDT on November 7, 2018, by
dialing 855-859-2056 within the U.S. and Canada, or 1-404-537-3406
internationally, using the passcode 7398818. The webcast of the
conference call will be archived and accessible through October 18,
2019, on the LabCorp
Investor Relations website.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life
sciences company that is deeply integrated in guiding patient care,
providing comprehensive clinical laboratory and end-to-end drug
development services. With a mission to improve health and improve
lives, LabCorp delivers world-class diagnostic solutions, brings
innovative medicines to patients faster and uses technology to improve
the delivery of care. LabCorp reported net revenues of more than $10
billion for 2017. To learn more about LabCorp, visit www.labcorp.com,
and to learn more about Covance Drug Development, visit www.covance.com.

This press release contains forward-looking statements including but
not limited to statements with respect to estimated 2018 guidance and
the related assumptions, the impact of various factors on operating and
financial results, expected savings and synergies (including from the
LaunchPad initiative and from acquisitions), and the opportunities for
future growth. Each of the forward-looking statements is subject to
change based on various important factors, including without limitation,
competitive actions and other unforeseen changes and general
uncertainties in the marketplace, changes in government regulations,
including healthcare reform, customer purchasing decisions, including
changes in payer regulations or policies, other adverse actions of
governmental and third-party payers, changes in testing guidelines or
recommendations, adverse results in material litigation matters, the
impact of changes in tax laws and regulations, failure to maintain or
develop customer relationships, our ability to develop or acquire new
products and adapt to technological changes, failure in information
technology, systems or data security, employee relations, and the effect
of exchange rate fluctuations. Actual results could differ materially
from those suggested by these forward-looking statements. The Company
has no obligation to provide any updates to these forward-looking
statements even if its expectations change. Further information on
potential factors, risks and uncertainties that could affect operating
and financial results is included in the Company’s Form 10-K for the
year ended December 31, 2017, and subsequent Forms 10-Q, including in
each case under the heading risk factors, and in the Company’s other
filings with the SEC. The information in this press release should be
read in conjunction with a review of the Company’s filings with the SEC
including the information in the Company’s Form 10-K for the year ended
December 31, 2017, and subsequent Forms 10-Q, under the heading
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.